Notch signaling is an ancient intercellular signaling mechanism that plays myriad roles during vascular development and physiology in vertebrates. These roles include regulation of artery/vein differentiation in endothelial and vascular smooth muscle cells, regulation of blood vessel sprouting and branching during both normal development and tumor angiogenesis, and the differentiation and physiological responses of vascular smooth muscle cells. Defects in Notch signaling also cause inherited vascular and cardiovascular diseases. In this review, I summarize recent findings and discuss the growing relevance of Notch pathway modulation for therapeutic applications in disease.
The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. Notch signaling frequently plays a crucial role in precursor cells making binary cell fate decisions. However, Notch signaling also regulates boundary formation between cell populations, cell proliferation and cell death. In addition, perturbations in Notch signaling contribute to the pathogenesis of several inherited human diseases and cancers. In this review, I will highlight the multiple roles that the Notch signaling pathway plays during vascular development and physiology in vertebrates.
Core components of the Notch signaling pathway
Notch family receptors are large single-pass type I transmembrane proteins (Fig. 1). In mammals, four Notch family receptors have been described: NOTCH1 through to NOTCH4. The extracellular domain of Notch family proteins contains up to 36 tandemly repeated copies of an epidermal growth factor (EGF)-like motif. Each Notch family receptor exists at the cell surface as a proteolytically cleaved heterodimer comprising a large ectodomain and a membrane-tethered intracellular domain. Notch receptors interact with single-pass type I transmembrane ligands expressed on neighboring cells. This restricts the Notch pathway to regulating short-range intercellular interactions. In mammals, the Notch ligands are encoded by the Jagged (JAG1 and JAG2) and Delta-like (DLL1, DLL3 and DLL4) gene families.
Upon ligand binding, a signal is transmitted intracellularly by a process involving the proteolytic cleavage of the receptor and the subsequent nuclear translocation of the Notch intracellular domain (NICD). The receptor-ligand interaction induces two additional proteolytic cleavages in the membrane-tethered fragment of the Notch heterodimer. The final cleavage, catalyzed by the γ-secretase complex, frees the NICD from the cell membrane. This cleaved fragment translocates to the nucleus because of the presence of nuclear localization signals located in the NICD. Once in the nucleus, the NICD forms a complex with the recombination signal binding protein for immunoglobulin kappa J region (RBPJ) protein - a sequence-specific DNA-binding protein. In the absence of the NICD, the RBPJ protein binds to specific DNA sequences in the regulatory elements of various target genes and represses transcription of these genes by recruiting histone deacetylases and other components to form a co-repressor complex. The nuclear translocation of the NICD displaces the histone deacetylase-co-repressor complex from the RBPJ protein. The NICD-RBPJ complex recruits other proteins, such as the mastermind-like 1 (MAML1) protein and histone acetyltransferases, leading to the transcriptional activation of Notch target genes. Among the most commonly induced Notch target genes are the basic helix-loop-helix (bHLH) transcriptional repressors of the hairy and enhancer of split/hairy and enhancer of split related with YRPW motif (Hes/Hey) family (Kageyama et al., 2007). Further details on the biochemistry of the Notch signaling pathway can be found in several recent reviews (Bray, 2006; Ehebauer et al., 2006a; Ehebauer et al., 2006b; Ilagan and Kopan, 2007; Kageyama et al., 2007; Le Borgne, 2006).
A role for the Notch pathway in regulating vascular development was initially suggested based on findings from the analysis of several targeted mouse mutants in Notch pathway components. Mouse mutants for which targeted mutagenesis and transgenic studies have demonstrated a role in embryonic vascular development include the receptors Notch1 (Huppert et al., 2000; Krebs et al., 2000; Limbourg et al., 2005) and Notch4 (Carlson et al., 2005; Krebs et al., 2000; Uyttendaele et al., 2001); the ligands Jag1 (Xue et al., 1999) and Dll4 (Duarte et al., 2004; Gale et al., 2004; Krebs et al., 2004); the Notch transcriptional regulator Rbpj (Krebs et al., 2004); the E3 ubiquitin ligase Mib1 (Barsi et al., 2005; Koo et al., 2005); components of the γ-secretase complex, such as nicastrin (Li et al., 2003), presenilin 1 and presenilin 2 (Herreman et al., 1999); and the Notch pathway downstream effector bHLH proteins Hey1 and Hey2 (Fischer et al., 2004; Kokubo et al., 2005). Most of these mutants exhibit a similar phenotype characterized by the absence of angiogenic vascular remodeling in the extraembryonic yolk sac, placenta and embryo proper (Fig. 2). However, an analysis of zebrafish embryos with reduced Notch signaling gave the first clues that a primary function of the Notch pathway during vascular development was to regulate the specification of arterial fate in endothelial cells.
It had long been believed that the primary factor that regulates the differentiation of arteries and veins was blood flow. The endothelial cells that line arteries experience higher blood pressures, higher rates of hemodynamic flow and higher oxygen tensions than do the endothelial cells that line veins. However, as described below, recent work has established that genetic pre-patterning, largely mediated by the Notch pathway, plays a primary role in regulating arteriovenous differentiation. This genetically determined pre-pattern is established prior to the initiation of blood flow, but endothelial cells at this stage are not yet committed to an arterial or venous cell fate (Jones et al., 2006). Indeed, recent work has established that, in zebrafish, a single hemangioblast, the bipotential precursor of a subset of hematopoietic and endothelial cells, can give rise to endothelial cell progeny that populate both arteries and veins (Vogeli et al., 2006).
The role of the Notch pathway in regulating early embryonic vascular development is intertwined with that of another major regulator of vascular development and physiology, the vascular endothelial growth factor A (VEGFA) pathway. VEGFA is a secreted glycoprotein that is a potent inducer of angiogenesis that also regulates multiple other aspects of blood vessel homeostasis (Byrne et al., 2005; Coultas et al., 2005; Shibuya and Claesson-Welsh, 2006). The roles and interdependence of the Notch and VEGFA pathways in regulating the formation of the large axial blood vessels of the trunk - the dorsal aorta and the posterior cardinal vein - was studied first in zebrafish (Lawson et al., 2001; Lawson et al., 2002). Notch signaling-deficient embryos exhibit a poorly formed dorsal aorta and posterior cardinal vein with accompanying arteriovenous malformations (the fusion of arteries and veins without an intervening capillary bed). These embryos also exhibited a loss of expression of arterial markers such as ephrin B2 from arterial vessels with an accompanying expansion of venous markers into normally arterial domains. Embryos in which Notch signaling had been ectopically activated exhibited the reverse phenotype: suppression of vein-specific markers with ectopic expression of arterial markers in venous vessels (Lawson et al., 2001). A similar phenotype was observed in embryos mutant for certain Notch target genes, such as the bHLH transcriptional repressor hey2 (also referred to in zebrafish as the gridlock gene) (Zhong et al., 2001; Zhong et al., 2000).
This analysis of the formation of the major trunk vessels in the zebrafish embryo revealed a signaling cascade that is responsible for determining arterial and venous cell fates in these vessels (Lawson et al., 2002) (Fig. 3). A reduction in vegfa activity results in a loss of arterial marker expression from the dorsal aorta and in the ectopic arterial expression of vein markers. Conversely, the injection of vegfa mRNA induces ectopic expression of the arterial marker ephrin B2 in the posterior cardinal vein. vegfa expression is regulated by the expression of the secreted morphogen sonic hedgehog a (shha) along the axial midline. Similar to what is observed in vegfa-deficient embryos, shha mutant zebrafish embryos also exhibit a loss of arterial differentiation, whereas injection of shha mRNA causes the ectopic expression of arterial markers. shha acts upstream of vegfa, because the injection of vegfa mRNA into shha mutant embryos restores normal arterial differentiation. This work also demonstrated that, in this setting, the Notch pathway acts downstream of the Vegfa pathway. Whereas injection of vegfa mRNA into Notch signaling-deficient zebrafish embryos could not rescue arterial marker gene expression, the expression of an activated notch1a transgene in vegfa-deficient embryos could rescue the expression of arterial markers (Lawson et al., 2002).
Studies in mammalian cell culture have also placed the Notch pathway downstream of the Vegfa pathway. VEGFA administration induces NOTCH1 and DLL4 expression in human arterial endothelial cells, but not in venous endothelial cells (Liu et al., 2003). Targeted-mutagenesis studies in mice have also demonstrated that Vegfa is essential for vascular development. Mouse embryos heterozygous for a Vegfa targeted mutation exhibit lethal haploinsufficiency (Carmeliet et al., 1996; Ferrara et al., 1996). Blood vessels, despite forming in these embryos, are severely constricted or atretic. It is not known whether artery-vein differentiation is compromised in Vegfa+/- mouse embryos. However, other gain-of-function transgenic experiments have demonstrated a role of Vegfa in regulating arterial endothelial cell differentiation in mice. Alternative splicing of the mouse Vegfa gene results in the production of several different protein isoforms (Vegfa 120, Vegfa 164 and Vegfa 188). Genetically engineered mice that express only the Vegfa 164 isoform display normal retinal vascular development. However, mice that express only Vegfa 120 exhibit severe defects in retinal vascular outgrowth, whereas mice expressing only Vegfa 188 exhibit impaired retinal arterial development, but normal venous development (Stalmans et al., 2002). Vegfa 164 overexpression in cardiac muscle increased the number of ephrin B2 (Efnb2)-positive capillaries in the mouse heart while reducing the number of ephrin receptor B4 (EphB4)-positive venules (Visconti et al., 2002). Vegfa could induce ephrin B2 gene expression in mouse primary embryonic endothelial cells, and Vegfa derived from sensory neurons, motor neurons and Schwann cells is required for arterial differentiation of small-diameter nerve-associated vessels in mice (Mukouyama et al., 2005; Mukouyama et al., 2002).
In mice, Dll4 is the primary Notch ligand required for vascular development. Similarly to Vegfa+/- heterozygous mouse embryos, Dll4+/- heterozygous embryos on inbred genetic backgrounds exhibit embryonic lethal haploinsufficiency due to vascular defects (Duarte et al., 2004; Gale et al., 2004; Krebs et al., 2004). However, some Dll4+/- mice are viable on an outbred background, permitting the examination of Dll4-/- embryos. The phenotype of Dll4-/- homozygotes was similar, although more severe, than that of Dll4+/- heterozygous embryos (Duarte et al., 2004; Gale et al., 2004). Similar to that which is observed in Notch signaling-deficient zebrafish embryos, both Dll4-deficient embryos and other types of Notch signaling-deficient mouse embryos, such as Rbpj mutant and Hey1; Hey2 double-mutant embryos, do not express arterial markers (Duarte et al., 2004; Fischer et al., 2004; Gale et al., 2004; Kokubo et al., 2005; Krebs et al., 2004). In support of a direct role for Notch signaling in regulating the expression of important arterially expressed genes, Dll4-mediated Notch signaling induces ephrin B2 gene expression in cultured endothelial cells (Iso et al., 2006), and the ephrin B2 gene has recently been shown to be a direct Notch target (Grego-Bessa et al., 2007).
Little is known about the transcriptional regulation of genes that exhibit arterially restricted expression in early embryos. The forkhead (Fox; also known as winged helix) proteins are a large family of evolutionarily conserved transcription factors (Kaestner et al., 2000). Mouse embryos with compound mutations of the Foxc1 and Foxc2 genes, two related Fox family transcription factors, display defects in vascular remodeling in the yolk sac and embryo (Kume et al., 2001), accompanied by reduced or absent expression of arterial markers and the occurrence of arteriovenous malformations (Seo et al., 2006). This failure of arterial specification is likely to be due to disrupted regulation of Dll4 transcription. The Foxc1 and Foxc2 proteins directly activate Dll4 transcription through a Foxc-binding element in the upstream region of the Dll4 gene. These results demonstrate that the Foxc proteins are key transcriptional regulators that act upstream of the Notch pathway during arteriovenous differentiation (Seo et al., 2006). However, it is not known whether Foxc1 and Foxc2 expression is downstream, or independent of, Vegfa signaling.
As mentioned previously, Notch signaling-deficient zebrafish embryos form arteriovenous malformations. Arteries normally connect to veins only through an intervening capillary bed. An aberrant direct communication between an artery and vein is termed an arteriovenous malformation. One mechanism that might explain the formation of arteriovenous malformations is the failure to establish or maintain distinct arterial and venous vascular beds. In mouse embryos, injection of ink into the heart is an effective way to visualize the presence of arteriovenous malformations (Sorensen et al., 2003). In Notch signaling-deficient mouse embryos (e.g. Dll4+/- or Notch1-/- embryos) arteriovenous malformations that are also detectable by histological analysis (Duarte et al., 2004; Gale et al., 2004; Krebs et al., 2004) form (Fig. 4) (Krebs et al., 2004). Interestingly, the inducible expression of an activated Notch4 transgene in adult mice results in vessel arterialization, such as the induction of venous expression of the ephrin B2 gene, and causes arteriovenous malformations in several organs, including liver, uterus and skin (Carlson et al., 2005). Surprisingly, these malformations are reversible if activated Notch4 transgene expression is repressed. These studies demonstrate that the ability of Notch signaling to arterialize blood vessels is not confined to the embryonic period. Although gain-of-function in vivo assays using the expression of an activated Notch4 transgene can cause mutant vascular phenotypes (Carlson et al., 2005; Uyttendaele et al., 2001), it should be noted that no obvious phenotype is observed in Notch4-/- mice (Krebs et al., 2000).
In addition to regulating arterial specification of endothelial cells, Notch signaling also regulates arterial specification of vascular smooth muscle cells. The Notch3 gene is expressed in vascular smooth muscle cells of arteries, but not in those of veins. Marked arterial defects occur in Notch3-/- mice, including enlarged arteries with a thinner vascular smooth muscle cell coat than is found in wild-type arteries (Domenga et al., 2004). These defects arise postnatally, because arterial vessels fail to mature. Morphologically, arterial vascular smooth muscle cells of Notch3-/- mice resemble those surrounding veins in wild-type mice. Only a few markers are known to be expressed predominantly in arterial vascular smooth muscle cells and not in venous ones. These include smoothelin (van der Loop et al., 1997) and a transgenic line expressing the β-galactosidase protein from arterial-specific regulatory elements of the SM22α promoter (Moessler et al., 1996). The expression of both of these markers is markedly downregulated in arteries of Notch3-/- mice (Fig. 5). Combined with the morphological data, this indicates that vascular smooth muscle cells that surround arteries in Notch3-/- mice have acquired a venous fate. Notably, in arteries of Notch3-/- mice, which do not express arterial markers for vascular smooth muscle cells, normal expression of several endothelial cell arterial markers occurs, including that of ephrin B2, connexin 40 (also known as Gja5 - Mouse Genome Informatics), Hes1, Hey1, Hey2 and Heyl (Domenga et al., 2004). These results demonstrate that the arterial identity of endothelial cells, and of the vascular smooth muscle cells surrounding them, is specified independently.
Endothelial tip cell differentiation
During angiogenesis, new capillaries sprout from existing blood vessels. Tip cells are specialized endothelial cells situated at the tips of vascular sprouts that extend filopodia in response to cues within the local extracellular environment, guiding the growth of these sprouts along Vegfa gradients (Gerhardt et al., 2003; Gerhardt et al., 2004). Recent work has identified a primary role for the Notch pathway in regulating the formation and function of these endothelial tip cells, a role that was first described several years ago (Sainson et al., 2005). In an in vitro angiogenesis culture system using human umbilical vein endothelial cells (HUVECs), Notch signaling inhibits branching at the tip of developing angiogenic sprouts. The suppression of Notch signaling led to tip cell division, with both daughter cells being specified as tip cells. This subsequently led to increased branching as a result of vessel bifurcation.
Numerous recent papers have confirmed and extended our understanding of the role of Notch signaling in tip cell formation. DLL4/Notch signaling has now been demonstrated to regulate tip cell numbers, filopodia extension in tip cells and the branching of angiogenic sprouts in HUVECs, as well as in several additional model systems: the mouse retina and hindbrain (Hellstrom et al., 2007; Lobov et al., 2007; Ridgway et al., 2006; Suchting et al., 2007); the zebrafish embryo (Leslie et al., 2007; Siekmann and Lawson, 2007); and xenograft tumor models (Noguera-Troise et al., 2006; Ridgway et al., 2006; Scehnet et al., 2007). A finding common to all of these studies is the increased sprouting and branching of blood vessels when Notch signaling is inhibited. The Notch pathway regulates sprouting and branching behaviors in these vessels by influencing the differentiation, migration and proliferation of vascular tip cells; reduced Notch signaling leads to increases in tip cell numbers, filopodia extension and vessel branching. Suppression of tip cell formation and angiogenic sprouting by Notch signaling is downstream of the VEGFA signal, because pharmacological or genetic manipulations that block VEGFA function reduce both DLL4 expression and blood vessel sprouting.
Several of these recent studies have assessed the effects of modulating Notch signaling on the differentiation of the developing retinal vasculature in mice (Hellstrom et al., 2007; Lobov et al., 2007; Ridgway et al., 2006; Suchting et al., 2007). Compared with other organs, the mouse retina possesses several distinct advantages for the analysis of developmental angiogenesis (Dorrell and Friedlander, 2006; Gariano and Gardner, 2005; Uemura et al., 2006). The mouse retinal vascular system develops postnatally in a highly reproducible spatial and temporal pattern. The retinal vascular system emerges first in the region of the optic nerve head, and then grows radially towards the periphery. The primitive vascular plexus that forms initially is then remodeled into large and small arterial and venous vessels. During these stages, the retinal vasculature is accessible both for observation and for the experimental administration of exogenous agents.
The Dll4 gene is highly expressed in the developing retinal vasculature, and reduced Dll4/Notch signaling leads to striking defects in the early postnatal retinal vasculature. The observed defects are concordant whether Dll4/Notch signaling is reduced genetically, by assessing Dll4+/- heterozygous mice (Hellstrom et al., 2007; Lobov et al., 2007; Suchting et al., 2007) or mice with temporally-regulated Notch1 deletion in the retinal vasculature (Hellstrom et al., 2007), or by administering anti-Dll4 blocking reagents (Lobov et al., 2007; Ridgway et al., 2006) orγ -secretase inhibitors (Hellstrom et al., 2007; Suchting et al., 2007). The retinal vasculature in these mice displays severe patterning defects (Fig. 6). The vascular plexus has an increased capillary density and diameter, with increased filopodial extensions both at the growing vascular front, and in the interior of the plexus. Furthermore, portions of the vascular plexus fuse to form syncytial sinuses. Markers specific for tip cells, such as platelet derived growth factor receptor beta (Pdgfrb) and unc-5 homolog B (Unc5b), are also upregulated in mice with reduced Dll4/Notch signaling. These data indicate that Dll4/Notch signaling restricts the acquisition of an endothelial tip cell fate in angiogenic sprouts.
Additional insights into endothelial tip cell formation, migration and behavior have been obtained from the analysis of the vasculature of zebrafish embryos (Leslie et al., 2007; Siekmann and Lawson, 2007). The optical clarity of these embryos and the availability of several transgenic lines that express fluorescent proteins in endothelial cells makes this animal model an ideal system for high-resolution fluorescent microscopy, including live time-lapse confocal microscopy. Mosaic analysis has revealed that transplanted cells that lack rbpj function do not contribute to the dorsal aorta, but become located preferentially in the posterior cardinal vein or the most dorsal position of the segmental arteries. Conversely, transplanted cells that express activated Notch1 become located preferentially in the dorsal aorta or the base of developing sprouts (Siekmann and Lawson, 2007). These results indicate that Notch signaling is required cell-autonomously to specify endothelial cell fate in segmental artery sprouts. The use of time-lapse confocal microscopy on living embryos revealed that, in both dll4 morphant and rbpj morphant embryos, segmental artery sprouts contain more cells than in controls. These additional cells are incorporated via both the increased migration of endothelial cells into the initial sprout, and by the proliferation of normally quiescent stalk cells. Interestingly, vascular defects in rbpj morphant embryos are more severe than those in dll4 morphant embryos, suggesting that additional Notch ligands play important roles during early vascular development (Leslie et al., 2007; Siekmann and Lawson, 2007). Blocking Vegfa signaling with a small molecule inhibitor prevents both normal endothelial sprouting and the ectopic sprouting observed in dll4 morphant embryos (Leslie et al., 2007). In addition, the reduction of Vegf receptor 3 (also known as Flt4 - Zebrafish Information Network) levels in rbpj morphant embryos partially rescues the rbpj-knockdown phenotype, suggesting that Notch activation might normally repress Vegf receptor 3 and thus limit angiogenic cell behavior in developing segmental artery sprouts (Siekmann and Lawson, 2007). Taken together, the studies in both the mouse retina and the zebrafish embryo indicate that Notch signaling acts as a negative regulator of Vegfa-induced angiogenesis, and is essential for proper vascular morphogenesis.
The maintenance, growth and metastasis of solid tumors require the recruitment of host blood vessels into the tumor. Many solid tumors express VEGFA, and therapies that use anti-Vegfa antibodies or other blocking reagents effectively inhibit solid tumor growth in preclinical rodent models (Ferrara and Kerbel, 2005; Jain et al., 2006). Given the prominent role of the Notch pathway in regulating vascular development, protein components of the Notch pathway might provide novel drug targets during tumor angiogenesis. Dll4 is expressed at high levels in tumor vasculature (Gale et al., 2004; Hainaud et al., 2006; Mailhos et al., 2001; Patel et al., 2005), and several recent studies have identified the Dll4 protein as just such a therapeutic target (Noguera-Troise et al., 2006; Ridgway et al., 2006; Scehnet et al., 2007). The systemic administration of neutralizing anti-Dll4 antibodies (Noguera-Troise et al., 2006; Ridgway et al., 2006), and the systemic (Noguera-Troise et al., 2006) or localized (Scehnet et al., 2007) administration of recombinant forms of the Dll4 protein that have been modified to block Dll4/Notch signaling, inhibit the growth of several different solid tumors in mice. Similar to the findings in zebrafish embryos and mouse retinas, anti-Dll4 treatment increases blood vessel sprouting and branching, and leads to a marked increase in tumor blood vessel density in the treated tumors. Paradoxically, tumor growth was inhibited in these mice despite the increased blood vessel density. Analysis of the vascular network in the anti-Dll4-treated tumors by perfusion assays with fluorescent lectins or by assessing hypoxic regions in these tumors revealed that the newly induced vessels function inefficiently. Many of these vessels are not connected to the vascular network in the tumors, leading to poor perfusion, increased hypoxia and an overall inhibition of tumor growth. Importantly, anti-Dll4 therapies are effective against tumors that were resistant to anti-VEGFA treatments, and could provide synergistic effects against certain tumors when combined with anti-Vegfa therapies (Noguera-Troise et al., 2006; Ridgway et al., 2006).
Although the results from the studies described above are very promising, many issues remain to be resolved before anti-DLL4 treatments reach the clinic. For example, despite the efficacy of anti-VEGFA therapies in the treatment of xenograft tumor models in rodents, in clinical trials, anti-VEGFA antibody treatment of several cancer types has been found to only provide an overall survival benefit for patients when it is combined with conventional chemotherapy treatment (Ferrara and Kerbel, 2005; Jain et al., 2006). Similar issues might arise as anti-DLL4 treatments progress from preclinical models into human clinical trials. However, these promising studies present a novel therapeutic approach for cancer treatment, particularly for tumors that are unresponsive to anti-VEGFA therapies.
Vascular smooth muscle cell differentiation and physiology
It is clear that Notch signaling plays an important role in the differentiation, physiology and function of vascular smooth muscle cells. However, contradictory results suggest that its role might be context-, time- or cell line-dependent. Several groups have described a role for Notch signaling in repressing smooth muscle cell differentiation during in vitro cell culture, and that this repressive effect is likely to be mediated via the induction of the HEY2 protein (Doi et al., 2005; Morrow et al., 2005a; Proweller et al., 2005). However, more-recent studies have indicated that Notch signaling induces smooth muscle cell differentiation (Doi et al., 2006; High et al., 2007); JAG1-mediated Notch signaling is reported to promote smooth muscle cell differentiation both in human aortic smooth muscle cells and in a murine embryonic fibroblast cell line (Doi et al., 2006). Both smooth muscle myosin heavy chain (Doi et al., 2006) and smooth muscle α-actin (Noseda et al., 2006) were demonstrated to be direct Notch target genes. Furthermore, in vivo studies in which Notch signaling was inactivated specifically in mouse neural crest cells reveals that Notch signaling plays an essential role in the differentiation of cardiac neural crest cells into smooth muscle cells (High et al., 2007).
Several studies have characterized the expression of Notch pathway genes during the response to vascular injury (Campos et al., 2002; Doi et al., 2005; Lindner et al., 2001; Wang et al., 2002). The expression of several Notch pathway components, including Notch1, Notch3, Jag1, Jag2, Hey1 and Hey2, is modulated after experimentally induced vascular injury. The expression of the genes encoding these proteins is downregulated within the first 2 days following vascular injury, but is upregulated in comparison to uninjured contralateral control vessels at 7-14 days after injury. In support of a functional role for the modulation of Notch pathway components during the response to vascular injury, formation of the neointima (a thickened layer of vascular smooth muscle cells) after vascular injury was significantly decreased in Hey2-/- mice (Sakata et al., 2004). The culture of primary aortic vascular smooth muscle cells from Hey2-/- mice has revealed that these mutant cells proliferate at a reduced rate compared with wild-type cells. The overexpression of Hey1 (Wang et al., 2003) or Hey2 (Havrda et al., 2006) in vascular smooth muscle cells led to increased vascular smooth muscle cell proliferation associated with reduced levels of the cyclin-dependent kinase inhibitors p21waf1/cip1 (Cdkn1a) (Wang et al., 2003) or p27kip1 (Cdkn1b) (Havrda et al., 2006). The Hey2 protein directly interacts with the p27kip1 promoter to repress transcription (Havrda et al., 2006).
Mechanical forces are one of several factors implicated in regulating vascular smooth muscle cell differentiation and physiology. Adult vascular smooth muscle cells are not terminally differentiated and can exhibit substantial plasticity in their phenotype in response to local environmental changes. The exposure of primary human or rat vascular smooth muscle cells to cyclic mechanical strain during in vitro culture causes a significant reduction in NOTCH1 and NOTCH3 receptor expression, concomitant with an increase in the expression of vascular smooth muscle cell differentiation markers (Morrow et al., 2005a; Morrow et al., 2005b). Vascular smooth muscle cells that are exposed to mechanical strain also exhibit reduced proliferation and increased apoptosis. Overexpression of the NOTCH1 or NOTCH3 intracellular domains in vascular smooth muscle cells exposed to such mechanical strain restored the percentages of proliferative or apoptotic cells to the levels observed in unstrained cells. These results indicate that cyclic mechanical strain inhibits vascular smooth muscle cell growth while increasing apoptosis, and that these effects are mediated, at least in part, via the modulation of Notch signaling.
Vascular smooth muscle cell physiology: CADASIL
The importance of Notch signaling in vascular development is highlighted by the finding that mutations in several Notch pathway components cause inherited vascular or cardiovascular diseases. The vascular defects associated with two of these inherited diseases, Alagille syndrome and inherited bicuspid aortic valve, primarily affect the development and function of the heart (Box 1). A third disease, which is caused by mutations in the NOTCH3 gene (Joutel et al., 1996), is an inherited degenerative vascular disease that affects vascular smooth muscle cells. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, termed CADASIL, is the most common genetic form of stroke and vascular dementia (Kalaria et al., 2004). Affected individuals exhibit a variety of symptoms, including migraines, mood disorders, recurrent subcortical ischemic strokes, progressive cognitive decline, dementia and premature death. CADASIL is characterized by the progressive degeneration of vascular smooth muscle cells and the accumulation of granular osmiophilic material (GOM) within the smooth muscle cell basement membrane (Kalaria et al., 2004). GOM accumulation in vascular smooth muscle cells is one of the most distinguishing features of CADASIL.
All NOTCH3 mutations associated with CADASIL result in a gain or loss of a cysteine residue in one of the 34 EGF-like repeats in the extracellular domain of the NOTCH3 receptor. The characteristic nature of these mutations, in addition to the absence of any examples in CADASIL patients of mutations or deletions of the NOTCH3 gene that are obviously inactivating, strongly suggests that mutations that cause CADASIL are not NOTCH3-null alleles. In CADASIL patients, the ectodomain of the NOTCH3 protein accumulates in the cerebral microvasculature at the cytoplasmic membrane of vascular smooth muscle cells (Joutel et al., 2000), although it is controversial whether the NOTCH3 ectodomain constitutes part or all of the GOM deposits (Ishiko et al., 2006; Joutel et al., 2000).
Two different mouse models that express NOTCH3 proteins containing mutations found in CADASIL patients have been developed. In one model, an Arg142Cys knock-in mutation was introduced into the endogenous mouse Notch3 gene (Lundkvist et al., 2005). These mice do not exhibit any CADASIL-like morphological or behavioral phenotypes, even when homozygous for this mutation. The second model more successfully recapitulates the early, preclinical phase of CADASIL. To create this model, transgenic mice were generated that express a human NOTCH3 cDNA that contains a different CADASIL mutation, the Arg90Cys mutation, in vascular smooth muscle cells (Ruchoux et al., 2003). An age-dependent accumulation of the NOTCH3 ectodomain and of GOM deposits in vascular smooth muscle cells of both cerebral and peripheral arterioles is observed in these mice. However, despite GOM accumulation, no evidence of damage to the brain parenchyma is seen. Physiological studies of these NOTCH3 Arg90Cys transgenic mice revealed an impaired cerebral vasoreactivity that suggests either decreased relaxation or increased resistance of cerebral blood vessels (Lacombe et al., 2005). Isolated caudal arteries from the tails of these mice exhibit increased pressure-induced contraction and decreased flow-induced dilation (Dubroca et al., 2005). Transgenic mice that express either the wild-type human NOTCH3 protein or the human NOTCH3 Arg90Cys mutation were equally effective in rescuing the arterial defects of Notch3-/- mice. Furthermore, the expression of the mutant NOTCH3 Arg90Cys protein correctly regulates the in vivo expression of a Notch signaling reporter (Monet et al., 2007). These data suggest that novel pathogenic roles for CADASIL mutant proteins, rather than compromised NOTCH3 signaling activity, underlie the etiology of CADASIL. Further analysis and development of the NOTCH3 Arg90Cys mouse model should lead to valuable insights into the onset and progression of CADASIL, particularly during its early, preclinical stages.
Box 1. Notch signaling and inherited cardiovascular disease
Alagille syndrome is an autosomal dominant disorder characterized by developmental abnormalities of the liver, heart, eye, skeleton and, at lower penetrance, several other organs (Gridley, 2003). Most cases of Alagille syndrome are caused by JAG1 mutations (Warthen et al., 2006), although a small number of Alagille syndrome patients with NOTCH2 mutations have been identified (McDaniell et al., 2006). The cardiac defects associated with Alagille syndrome include pulmonary artery stenosis and hypoplasia, pulmonic valve stenosis, and tetralogy of Fallot. These defects are likely to be due to a requirement for Notch signaling-mediated differentiation of cardiac neural crest cells into smooth muscle cells, which has been demonstrated in a mouse model (High et al., 2007).
Bicuspid aortic valve affects 1-2% of the population, making it the most common congenital cardiac malformation (Braverman et al., 2005; Garg, 2006). Bicuspid aortic valve predisposes one to aortic valve calcification, which can impair blood flow through the valve. Aortic valve calcification was linked to Notch regulation of the transcription factor RUNX2 (Garg, 2006; Garg et al., 2005). Heterozygous mutations in the NOTCH1 gene were found in two families with autosomal-dominant aortic valve disease (Garg et al., 2005). NOTCH1 mutations are also found in 4% of sporadic bicuspid aortic valve patients (Mohamed et al., 2006). The formation of bicuspid aortic valve might reflect the role of Notch signaling in regulating the epithelial-mesenchymal transition required for the generation of the heart valves (Fischer et al., 2007; Noseda et al., 2004; Timmerman et al., 2004).
As can be seen by the recent flurry of publications that focus on the role of Notch signaling in regulating endothelial tip cell formation and the resulting implications for tumor angiogenesis (Hellstrom et al., 2007; Leslie et al., 2007; Lobov et al., 2007; Noguera-Troise et al., 2006; Ridgway et al., 2006; Scehnet et al., 2007; Siekmann and Lawson, 2007; Suchting et al., 2007), we still have much to learn about the roles that the Notch pathway plays in the vasculature. How are the different roles that the Notch pathway plays in, for example, arteriovenous patterning, tip cell differentiation, and vessel wall formation, integrated during vascular development and physiology? Are these roles related mechanistically, or do they represent different aspects of Notch pathway function? What is the contribution of Notch signaling during normal vascular physiology in adults, and how do perturbations in Notch signaling contribute to vascular pathology and disease?
Areas in which there will certainly be significant advances in upcoming years include the development of anti-DLL4 therapies (and possibly other types of `anti-Notch' therapies) that target tumor angiogenesis as well as other vascular diseases characterized by pathological angiogenesis, such as neovascular age-related macular degeneration and diabetic retinopathy. We are also likely to see the development and characterization of better animal models for CADASIL. Because CADASIL causes the most common form of inherited stroke and vascular dementia in humans, animal models that better recapitulate the pathological and behavioral abnormalities exhibited by CADASIL patients will permit the development and evaluation of therapeutic treatment regimens both for CADASIL and for sporadic cases of vascular dementia. Significant advances in our understanding of the mechanisms for cross-talk between the Notch pathway and other signaling pathways, such as the TGFβ, Wnt, ephrin/Eph receptor and PI3K/Akt pathways, and in the developmental and physiological decisions in which such cross-talk is operative, are also likely to occur in the near future. The answers to these and other questions will keep Notch pathway researchers occupied for many years to come.
I apologize to colleagues whose work could not be cited directly due to space constraints. I thank Anne Joutel, Anne Eichmann and Luke Krebs for images for some of the figures. Work in my laboratory on the Notch pathway is supported by the National Institutes of Health.
- © 2007.